TENSHA THERAPEUTICS
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The companyรขโฌลธs programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The companyรขโฌลธs lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.
TENSHA THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Pharmaceutical
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.tenshatherapeutics.com
Total Employee:
10001+
Status:
Active
Contact:
+41 61 688 11 11
Email Addresses:
[email protected]
Total Funding:
15 M USD
Technology used in webpage:
SPF Safenames
Similar Organizations
Cullinan Pearl
Cullinan Pearl develops an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations.
GIRx
GIRx is developing small molecule agents to treat diabetes, obesity and other metabolic conditions.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
Torrey Pines Investment
Torrey Pines Investment investment in Funding Round - Tensha Therapeutics
HealthCare Ventures
HealthCare Ventures investment in Series A - Tensha Therapeutics
Official Site Inspections
http://www.tenshatherapeutics.com
- Host name: redirect.idp365.net
- IP address: 217.19.248.132
- Location: Milton Keynes United Kingdom
- Latitude: 52.0675
- Longitude: -0.7569
- Timezone: Europe/London
- Postal: MK14
More informations about "Tensha Therapeutics"
Tensha Therapeutics Company Profile 2024: Valuation, Investors ...
Tensha Therapeutics General Information Description. Developer of anti-cancer compound for curing acute myeloid leukemia. The company develops small molecule bromodomain โฆSee details»
Tensha Therapeutics - VentureRadar
Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The โฆSee details»
Tensha Therapeutics, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Tensha Therapeutics, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Roche acquires Tensha Therapeutics - 2016-01-11 - Crunchbase
Acquired Organization: Tensha Therapeutics Tensha Therapeutics develops small molecule bromodomain inhibitors to treat cancer and other serious disorders. Acquiring Organization: โฆSee details»
Roche Takes a $535 Million Chance on Cambridge's Tensha โฆ
Jan 12, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tensha Therapeutics, a privately-held company based in Cambridge, MA, announced today it will be acquired by Roche.Founded by โฆSee details»
Tensha Therapeutics To Be Acquired By Roche - Business Wire
Jan 11, 2016 For more information on Tensha, visit www.tenshatherapeutics.com. Contacts Tensha Therapeutics Douglas E. Onsi, 617-218-1116 President & CEO, Tensha Therapeutics โฆSee details»
Tensha Therapeutics Inc - Company Profile and News
Company profile page for Tensha Therapeutics Inc including stock price, company news, executives, board members, and contact informationSee details»
Tensha Therapeutics to be Acquired by Roche - Technology โฆ
Jan 12, 2016 Founded by James E. Bradner, MD, formerly of the Dana-Farber Cancer Institute, and managed and funded by HealthCare Ventures, Tensha has developed a pioneering โฆSee details»
Tensha Therapeutics : To Be Acquired By Roche - MarketScreener
Jan 11, 2016 Tensha Therapeutics, a privately-held company based in Cambridge, MA, announced today it will be acquired by Roche. Founded by James E. Bradner, MD, of the โฆSee details»
Tensha Therapeutics - Funding, Financials, Valuation & Investors
Organization. Tensha Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Funding Rounds 2. ... Venture โฆSee details»
Tensha Therapeutics Completes $15 Million Series A Financing to โฆ
CAMBRIDGE, Mass., Sep 12, 2011 (BUSINESS WIRE) -- Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small โฆSee details»
Roche Acquires Tensha Therapeutics for $115M Upfront
Jan 11, 2016 Roche will acquire Tensha Therapeutics for an upfront cash payment of $115 million, plus additional contingent payments of up to $420 million. Tensha, which was founded โฆSee details»
Roche bets on bromodomains | Nature Biotechnology
Apr 7, 2016 Proteins containing bromodomains are part of the body's epigenetic machinery. Modifications that occur on chromatin to influence gene expression are believed to be one of โฆSee details»
Tensha Therapeutics Emerges With $15 Million Funding
Sep 12, 2011 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of โฆSee details»
Cambridge, MA startup lands $15M A round for cancer drug pipeline
Sep 12, 2011 Cambridge, MA-based Tensha Therapeutics has come out of stealth mode with a $15 million Series A in an unusual solo venture round provided entirely by HealthCare โฆSee details»
Tensha Therapeutics - Contacts, Employees, Board Members
Organization. Tensha Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 2. About. โฆSee details»
Tensha Therapeutics completes $15M Series A financing to โฆ
Sep 12, 2011 Tensha Therapeutics announced today that it has raised $15 million in a Series A financing to advance the development of small molecule bromodomain inhibitors for the โฆSee details»
Tensha Therapeutics - Nature Biotechnology
Apr 10, 2012 Tensha's scientific focus stems from the academic research of James (Jay) Bradner at the Dana-Farber Cancer Institute in Boston. Bradner's laboratory is broadly โฆSee details»
Tensha Therapeutics Completes $15 Million Series A Financing to โฆ
Sep 12, 2011 Tensha Therapeutics Raises $15 million to advance bromodomain inhibitors for cancer. Tensha's lead program is aimed at midline carcinoma, acute myeloiSee details»